Merz Pharma, a global provider of aesthetic products and neurotoxins, has appointed Bob Rhatigan as president and chief executive officer (CEO) of Merz North America and Patrick Urban as chief commercial officer, effective immediately. Both Rhatigan and Urban will be based in Raleigh, North Carolina.
Prior to joining Merz, Rhatigan served as president and chief operating officer at Alphaeon Corporation, a healthcare company focused on the lifestyle medical space, as well as senior vice president of Allergan’s Facial Aesthetics business. While at Allergan, he also served as senior vice president, general manager and chief executive of SkinMedica.
In his new role, Rhatigan will assume responsibility for Merz’s business in North America, leading strategy and operations across the U.S. and Canada. He will join Merz’s global management board and will report directly to Philip Burchard, CEO of Merz Pharma Group.
“I am honored and excited to lead the Merz North America team to an even higher level of achievement and ensure a successful future for the organization. We have a well-rounded and strong portfolio in which I see clear potential,” said Rhatigan. “I am fortunate to work with a deeply experienced senior leadership team as we continue to target innovative approaches and growth opportunities with a strategic focus on our aesthetics and neurotoxins business. We will remain committed to being a trusted partner for our customers to provide long-term value as well as meet the evolving needs of our patients.”
Patrick Urban, who most recently served as interim president and CEO for Merz North America and has more than 20 years of commercial experience in the U.S. pharmaceutical and medical device industries, has accepted the role of chief commercial officer, reporting directly to Rhatigan. In this newly created position, Urban will play a critical role in driving the commercial success of the Merz Aesthetics portfolio.
Image: Bob Rhatigan